Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer
NCT00845884
Interventional
Phase 1/Phase 2
Unknown status
In spite of multiple attempts to improve the efficacy of first-line chemotherapy in advanced
gastric cancer, the progress that has been achieved so far is rather limited, and many
investigators are exploring newer regimens.A combination of decetaxel (Taxotere) with
Cisplatin and 5-fluorouracil (5FU) is considered one of the most effective regimens in this
disease. However, it is associated with significant toxicity which avoided its general
adaptation by the medical community. The current study is exploring a newer way to administer
these three drugs, hopefully making the regimen more comfortable, less toxic and maybe even
more effective. We will do this by changing the dose and timing of Taxotere and Cisplating,
by replacing protracted infusion of 5FU with tablets of Capecitabine (Xeloda) and by adding
the anti-angiogenic drug, Bevacizumab (Avastin), which had shown encouraging results in this
disease.
Feb 28,2009
Male
18 Years
N/A
18 Years
N/A
49